- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INMOLECULE NANOTECH Aktie jetzt für 0€ handeln | |||||
| 26.09.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 26.09.2025 | 842 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.09.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.09.2025
Aktien
1 SE0023135298 NOBA Bank Group AB
2... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 19,330 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| VERA THERAPEUTICS | 38,200 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| ADITXT | 0,042 | 0,00 % | Aditxt, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 305,35 | -0,01 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 98,15 | -0,10 % | Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? | ||
| DISC MEDICINE | 70,45 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| BOUNDLESS BIO | 2,610 | +0,38 % | Boundless Bio, Inc.: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement | Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha's lead program SERP-01 targets the... ► Artikel lesen | |
| KAILERA THERAPEUTICS | 21,370 | 0,00 % | Kailera Therapeutics, Inc.: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,590 | -0,02 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More | ||
| NURIX THERAPEUTICS | 18,860 | 0,00 % | Nurix, BioNxt Solutions, Zealand Pharma - Neue Therapien sorgen für Fantasie | Der Biotech-Sektor erlebt derzeit eine Phase enormer Dynamik. Besonders Therapien gegen Adipositas, Diabetes, Autoimmunerkrankungen und neurologische Leiden zählen zu den größten Wachstumsmärkten im... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 59,50 | +0,02 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| TREVI THERAPEUTICS | 17,370 | -0,06 % | Trevi Therapeutics Aktie erreicht Rekordhoch von 16,13 USD | ||
| ERASCA | 15,070 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,240 | -0,10 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 33,740 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report |
Das Unternehmen INMOLECULE NANOTECH SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INMOLECULE NANOTECH SA finden Sie auf Wallstreet Online.